Free Trial
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Nabriva Therapeutics logo

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1 shs
Average Volume
29,344 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBRV Stock News Headlines

Nabriva Therapeutics plc (NBRVF)
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
Nabriva Therapeutics PLC NBRVF
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
See More Headlines

NBRV Stock Analysis - Frequently Asked Questions

Nabriva Therapeutics plc (NASDAQ:NBRV) released its earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company had revenue of $2.53 million for the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%.

Shares of Nabriva Therapeutics reverse split on the morning of Friday, September 16th 2022.The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/06/2021
Today
10/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBRV
CIK
1641640
Employees
70
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
($19.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.19 million
Net Margins
-148.11%
Pretax Margin
-144.78%
Return on Equity
-365.53%
Return on Assets
-135.81%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.85
Quick Ratio
0.52

Sales & Book Value

Annual Sales
$35.59 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
32,015,000
Free Float
31,493,000
Market Cap
$45.46 million
Optionable
Not Optionable
Beta
1.53

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:NBRV) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners